Skip to main content

Nontuberculous Mycobacterium Infection

2
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

LigaChem Biosciences
LigaChem BiosciencesKorea - Daejeon
1 program
1
DelpazolidPhase 21 trial
Active Trials
NCT06004037Active Not Recruiting20Est. Dec 2026
Oregon Therapeutics
Oregon TherapeuticsFrance - Paris
1 program
1
gNOPhase 21 trial
Active Trials
NCT03748992Completed10Est. Mar 2020

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
LigaChem BiosciencesDelpazolid
Oregon TherapeuticsgNO

Clinical Trials (2)

Total enrollment: 30 patients across 2 trials

Study to Evaluate the Efficacy of Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex

Start: Jan 2024Est. completion: Dec 202620 patients
Phase 2Active Not Recruiting

A Proof of Concept Study of Inhaled Nitric Oxide for Adults With Pulmonary Non-Tuberculous Mycobacterial Infection

Start: Jan 2019Est. completion: Mar 202010 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.